The adrenal medulla: Physiology and pathophysiology

Handbook of the Autonomic Nervous System in Health and Disease

Volumn , Issue , 2002, Pages 185-224

  Eisenhofer, Graeme ^a   Ehrhart Bornstein, Monika ^b   Bornstein, Stefan R ^b  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85014327519     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (191)

1. Takamine J. The isolation of the active principle of the suprarenal gland. J Physiol 1901; 27:30P-39P.
2. Cannon WB. The Wisdom of the Body. New York: WW Norton, 1939.
3. von Euler US. A specific sympathomimetic ergone in adrenergic nerve fibres (sym-pathin) and its relations to adrenaline and nor-adrenaline. Acta Physiol Scand 1946; 12:73-96.
4. Robertson DA, Johnson GA, Robertson RM, Nies AS, Shand DG, Oates JA. Comparative assessment of stimuli that release neuronal and adrenomedullary catecholamines in man. Circulation 1979; 59:637-643.
5. Axelrod J, Kopin IJ. The uptake, storage, release and metabolism of noradrenaline in sympathetic nerves. Prog Brain Res 1969; 31:21-32.
6. Ahlquist RP. A study of adrenotropic receptors. Am J Physiol 1948; 153:586-600.
7. Hjemdahl P, Belfrage E, Daleskog M. Vascular and metabolic effects of circulating epinephrine and norepinephrine. Concentration-effect study in dogs. J Clin Invest 1979; 64:1221-1228.
8. Warren JB, Dalton N. A comparison of the bronchodilator and vasopressor effects of exercise levels of adrenaline in man. Clin Sci 1983; 64:475-449.
9. Freyschuss U, Hjemdahl P, Juhlin-Dannfelt A, Linde B. Cardiovascular and sympathoadrenal responses to mental stress: influence of beta-blockade. Am J Physiol 1988; 255:H1443-H1451.
10. Macdonald IA, Bennett T, Fellows IW. Catecholamines and the control of metabolism in man. Clin Sci 1985; 68:613-669.
11. Cryer PE. Adrenaline: a physiological metabolic regulatory hormone in humans? Int J Obes Relat Metab Disord 1993; 17(suppl 3):S43-46.
12. Warren J. The adrenal medulla and the airway. Br J Dis Chest 1986; 80:1-6.
13. Cryer PE, Tse TF, Clutter WE, Shah SD. Roles of glucagon and epinephrine in hypoglycemic and nonhypoglycemic glucose counterregulation in humans. Am J Physiol 1984; 247:E198-205.
14. Hoelzer DR, Dalsky GP, Schwartz NS, Clutter WE, Shah SD, Holloszy JO, Cryer PE. Epinephrine is not critical to prevention of hypoglycemia during exercise in humans. Am J Physiol 1986; 251:E104-E110.
15. Lenders JW, Peters JH, Pieters GF, Willemsen JJ, Thien T. Hemodynamic reactivity to sympathoadrenal stimulation in adrenalectomized women. J Clin Endocrinol Metab 1988; 67:139-143.
16. Howlett K, Galbo H, Lorentsen J, Bergeron R, Zimmerman-Belsing T, Bulow J, Feldt-Rasmussen U, Kjaer M. Effect of adrenaline on glucose kinetics during exercise in adrenalectomised humans. J Physiol 1999; 519 Pt 3:911-921.
17. Coupland RE. Post-natal fate of the abdominal para-aortic bodies in man. J Anat 1954; 88:455-464.
18. Kreiner E. Weight and shape of the human adrenal medulla in various age groups. Virchows Arch A Pathol Anat Histol 1982; 397:7-15.
19. Padbury JF. Functional maturation of the adrenal medulla and peripheral sympathetic nervous system. Baillieres Clin Endocrinol Metab 1989; 3:689-705.
20. Coupland RE, Selby JE. The blood supply of the mammalian adrenal medulla: a comparative study. J Anat 1976; 122:539-551.
21. Murakami T, Oukouchi H, Uno Y, Ohtsuka A, Taguchi T. Blood vascular beds of rat adrenal and accessory adrenal glands, with special reference to the corti-comedullary portal system: a further scanning electron microscopic study of corrosion casts and tissue specimens. Arch Histol Cytol 1989; 52:461-476.
22. Hillarp NA, Hökfelt B. Evidence of adrenaline and noradrenaline in separate adrenal medullary cells. Acta Physiol Scand 1953; 30:55-68.
23. Brown WJ, Barajas L, Latta H. The ultrastructure of the human adrenal medulla: with comparative studies of white rat. Anat Rec 1971; 169:173-183.
24. Hansen JT, Notter MF, Okawara SH, Gash DM. Organization, fine structure, and viability of the human adrenal medulla: considerations for neural transplantation. Ann Neurol 1988; 24:599-609.
25. Vollmer RR. Selective neural regulation of epinephrine and norepinephrine cells in the adrenal medulla—cardiovascular implications. Clin Exp Hypertens 1996; 18:731-751.
26. Aunis D, Langley K. Physiological aspects of exocytosis in chromaffin cells of the adrenal medulla. Acta Physiol Scand 1999; 167:89-97.
27. Nagatsu T, Levitt M, Udenfriend S. Tyrosine hydroxylase, the initial step in norepinephrine biosynthesis. J Biol Chem 1964; 239:2910-2917.
28. Kawamura M, Eisenhofer G, Kopin IJ, Kador PF, Lee YS, Tsai JY, Fujisawa S, Lizak MJ, Sinz A, Sato S. Aldose reductase, a key enzyme in the oxidative deamination of norepinephrine in rats. Biochem Pharmacol 1999; 58:517-524.
29. Eisenhofer G, Lamensdorf I, Kirk KL, Kawamura M, Sato S. Oxidative deamination of monoamines and biogenic aldehydes in neurodegeneration. In: Creveling CR, ed. Role of Quinone Species in Cellular Toxicity. Johnson City, TN: F.P. Graham, 2000:103-145.
30. Eisenhofer G, Goldstein DS, Stull R, Ropchak TG, Keiser HR, Kopin IJ. Dihydrox-yphenylglycol and dihydroxymandelic acid during intravenous infusions of noradrenaline. Clin Sci 1987; 73:123-125.
31. Kawamura M, Kopin IJ, Kador PF, Sato S, Tjurmina O, Eisenhofer G. Effects of aldehyde/aldose reductase inhibition on neuronal metabolism of norepinephrine. J Auton Nerv Syst 1997; 66:145-148.
32. Eisenhofer G, Pecorella W, Pacak K, Hooper D, Kopin IJ, Goldstein DS. The neuronal and extraneuronal origins of plasma 3-methoxy-4-hydroxyphenylglycol in rats. J Auton Nerv Syst 1994; 50:93-107.
33. Blombery PA, Kopin IJ, Gordon EK, Markey SP, Ebert MH. Conversion of MHPG to vanillylmandelic acid. Implications for the importance of urinary MHPG. Arch Gen Psychiatry 1980; 37:1095-1098.
34. Märdh G, Anggärd E. Norepinephrine metabolism in man using deuterium labelling: origin of 4-hydroxy-3-methoxymandelic acid. J Neurochem 1984; 42:43-46.
35. Eisenhofer G, Aneman A, Hooper D, Rundqvist B, Friberg P. Mesenteric organ production, hepatic metabolism, and renal elimination of norepinephrine and its metabolites in humans. J Neurochem 1996; 66:1565-1573.
36. Dajani R, Cleasby A, Neu M, Wonacott AJ, Jhoti H, Hood AM, Modi S, Hersey A, Taskinen J, Cooke RM, Manchee GR, Coughtrie MW. X-ray crystal structure of human dopamine sulfotransferase, SULT1A3. Molecular modeling and quantitative structure-activity relationship analysis demonstrate a molecular basis for sulfotransferase substrate specificity. J Biol Chem 1999; 274:37862-37868.
37. Dajani R, Sharp S, Graham S, Bethell SS, Cooke RM, Jamieson DJ, Coughtrie MW. Kinetic properties of human dopamine sulfotransferase (SULT1A3) expressed in prokaryotic and eukaryotic systems: comparison with the recombinant enzyme purified from Escherichia coli. Protein Expr Purif 1999; 16:11-18.
38. Eisenhofer G, Coughtrie MW, Goldstein DS. Dopamine sulphate: an enigma resolved. Clin Exp Pharmacol Physiol 1999; 26:S41-S53.
39. Eisenhofer G, Rundqvist B, Aneman A, Friberg P, Dakak N, Kopin IJ, Jacobs MC, Lenders JW. Regional release and removal of catecholamines and extraneuronal metabolism to metanephrines. J Clin Endocrinol Metab 1995; 80:3009-3017.
40. Eisenhofer G, Friberg P, Pacak K, Goldstein DS, Murphy DL, Tsigos C, Quyyumi AA, Brunner HG, Lenders JW. Plasma metadrenalines: Do they provide useful information about sympatho-adrenal function and catecholamine metabolism? Clin Sci (Colch) 1995; 88:533-542.
41. Eisenhofer G, Keiser H, Friberg P, Mezey E, Huynh T-T, Hiremagalur B, Ellingson T, Duddempudi S, Eijsbouts A, Lenders J. Plasma metanephrines are markers of pheochromocytoma produced by catechol-O-methyltransferase within tumors. J Clin Endocrinol Metab 1998; 83:2175-2185.
42. Schultzberg M, Lundberg JM, Hokfelt T, Terenius L, Brandt J, Elde RP, Goldstein M. Enkephalin-like immunoreactivity in gland cells and nerve terminals of the adrenal medulla. Neuroscience 1978; 3:1169-1186.
43. Winkler H, Apps DK, Fischer-Colbrie R. The molecular function of adrenal chromaffin granules: established facts and unresolved topics. Neuroscience 1986; 18:261-290.
44. Ehrhart-Bornstein M, Hinson JP, Bornstein SR, Scherbaum WA, Vinson GP. In traadrenal interactions in the regulation of adrenocortical steroidogenesis. Endocr Rev 1998; 19:101-143.
45. Livett BG, Marley PD, Wan DC, Zhou XF. Peptide regulation of adrenal medullary function. J Neural Transm 1990; 29:S77-S89.
46. Winkler H, Fischer-Colbrie R. Regulation of the biosynthesis of large dense-core vesicles in chromaffin cells and neurons. Cell Mol Neurobiol 1998; 18:193-209.
47. Haidan A, Bornstein SR, Glasow A, Uhlmann K, Lubke C, Ehrhart-Bornstein M. Basal steroidogenic activity of adrenocortical cells is increased 10-fold by coculture with chromaffin cells. Endocrinology 1998; 139:772-780.
48. Huttner WB, Natori S. Regulated secretion. Helper proteins for neuroendocrine secretion. Curr Biol 1995; 5:242-225.
49. Hendy GN, Bevan S, Mattei MG, Mouland AJ. Chromogranin A. Clin Invest Med 1995; 18:47-65.
50. Hsiao RJ, Neumann HP, Parmer RJ, Barbosa JA, O’Connor DT. Chromogranin A in familial pheochromocytoma: diagnostic screening value, prediction of tumor mass, and post-resection kinetics indicating two-compartment distribution. Am J Med 1990; 88:607-613.
51. Langley K, Grant NJ. Molecular markers of sympathoadrenal cells. Cell Tissue Res 1999; 298:185-206.
52. Tschernitz C, Laslop A, Eiter C, Kroesen S, Winkler H. Biosynthesis of large dense-core vesicles in PC12 cells: effects of depolarization and second messengers on the mRNA levels of their constituents. Brain Res Mol Brain Res 1995; 31:131-140.
53. Siegel RE, Eiden LE, Pruss RM. Multiple populations of neuropeptide-containing cells in cultures of the bovine adrenal medulla. Brain Res 1985; 349:267-270.
54. Fischer-Colbrie R, Iacangelo A, Eiden LE. Neural and humoral factors separately regulate neuropeptide Y, enkephalin, and chromogranin A and B mRNA levels in rat adrenal medulla. Proc Natl Acad Sci 1988; 85:3240-3324.
55. Pruss RM, Mezey E, Forman DS, Eiden LE, Hotchkiss AJ, DiMaggio DA, O’-Donohue TL. Enkephalin and neuropeptide Y: two colocalized neuropeptides are independently regulated in primary cultures of bovine chromaffin cells. Neuropeptides 1986; 7:315-327.
56. Eskay RL, Eiden LE. Interleukin-1 alpha and tumor necrosis factor-alpha differentially regulate enkephalin, vasoactive intestinal polypeptide, neurotensin, and substance P biosynthesis in chromaffin cells. Endocrinology 1992; 130:2252-2228.
57. Beinfeld MC, Brick PL, Howlett AC, Holt IL, Pruss RM, Moskal JR, Eiden LE. The regulation of vasoactive intestinal peptide synthesis in neuroblastoma and chromaffin cells. Ann NY Acad Sci 1988; 527:68-76.
58. Vaupel R, Jarry H, Schlomer HT, Wuttke W. Differential response of substance P-containing subtypes of adrenomedullary cells to different stressors. Endocrinology 1988;123:2140-215.
59. Unsicker K, Krieglstein K. Growth factors in chromaffin cells. Prog Neurobiol 1996; 48:307-324.
60. Bieger SC, Henkel AW, Unsicker K. Localization of basic fibroblast growth factor in bovine adrenal chromaffin cells. J Neurochem 1995; 64:1521-1527.
61. Wurtman RJ, Axelrod J. Control of enzymatic synthesis of adrenaline in the adrenal medulla by adrenal cortical steroids. J Biol Chem 1966; 241:2301-2305.
62. Carballeira A, Fishman LM. The adrenal functional unit: a hypothesis. Perspect Biol Med 1980; 23:573-597.
63. Bornstein SR, Ehrhart-Bornstein M, Scherbaum WA, Pfeiffer EF, Holst JJ. Effects of splanchnic nerve stimulation on the adrenal cortex may be mediated by chromaffin cells in a paracrine manner. Endocrinology 1990; 127:900-906.
64. Bornstein SR, Gonzalez-Hernandez JA, Ehrhart-Bornstein M, Adler G, Scherbaum WA. Intimate contact of chromaffin and cortical cells within the human adrenal gland forms the cellular basis for important intraadrenal interactions. J Clin Endocrinol Metab 1994; 78:225-232.
65. Linares OA, Halter JB. Sympathochromaffin system activity in the elderly. J Am Geriatr Soc 1987; 35:448-453.
66. Esler M, Kaye D, Thompson J, Jennings G, Cox H, Turner A, Lambert G, Seals D. Effects of aging on epinephrine secretion and regional release of epinephrine from the human heart. J Clin Endocrinol Metab 1995; 80:435-442.
67. McCarty R, Pacak K, Goldstein DS, Eisenhofer G. Regulation of peripheral catecholamine responses to acute stress in young adult and aged F-344 rats. Stress 1997; 2:113-122.
68. Seals DR, Esler MD. Human ageing and the sympathoadrenal system. J Physiol 2001; 528:407-417.
69. Best JD, Halter JB. Release and clearance rates of epinephrine in man: importance of arterial measurements. J Clin Endocrinol Metab 1982; 55:263-268.
70. Marker JC, Clutter WE, Cryer PE. Reduced epinephrine clearance and glycemic sensitivity to epinephrine in older individuals. Am J Physiol 1998; 275:E770-E776.
71. Davidson L, Vandongen R, Rouse IL, Beilin LJ, Tunney A. Sex-related differences in resting and stimulated plasma noradrenaline and adrenaline. Clin Sci 1984; 67:347-352.
72. Gerlo EA, Schoors DF, Dupont AG. Age- and sex-related differences for the urinary excretion of norepinephrine, epinephrine, and dopamine in adults. Clin Chem 1991; 37:875-878.
73. Engstrom BE, Karlsson FA, Wide L. Gender differences in diurnal growth hormone and epinephrine values in young adults during ambulation. Clin Chem 1999; 45:1235-1239.
74. Gonzalez-Trapaga JL, Nelesen RA, Dimsdale JE, Mills PJ, Kennedy B, Parmer RJ, Ziegler MG. Plasma epinephrine levels in hypertension and across gender and ethnicity. Life Sci 2001; 66:2383-2392.
75. Swinyard CA. Growth of the human suprarenal glands. Anat Rec 1940; 87:141-150.
76. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnor-malities—the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996; 334:374-381.
77. Leonetti DL, Bergstrom RW, Shuman WP, Wahl PW, Jenner DA, Harrison GA, Fu-jimoto WY. Urinary catecholamines, plasma insulin and environmental factors in relation to body fat distribution. Int J Obes 1991; 15:345-357.
78. Landsberg L. Pathophysiology of obesity-related hypertension: role of insulin and the sympathetic nervous system. J Cardiovasc Pharmacol 1994; 23(suppl 1):S1-S8.
79. Ward KD, Sparrow D, Landsberg L, Young JB, Vokonas PS, Weiss ST. The relationship of epinephrine excretion to serum lipid levels: the Normative Aging Study. Metabolism 1994; 43:509-513.
80. Del Rio G. Adrenomedullary function and its regulation in obesity. Int J Obes Relat Metab Disord 2001; 24(suppl 2):S89-91.
81. Lee ZS, Critchley JA, Tomlinson B, Young RP, Thomas GN, Cockram CS, Chan TY, Chan JC. Urinary epinephrine and norepinephrine interrelations with obesity, insulin, and the metabolic syndrome in Hong Kong Chinese. Metabolism 2001; 50:135-143.
82. Jones PP, Davy KP, Alexander S, Seals DR. Age-related increase in muscle sympathetic nerve activity is associated with abdominal adiposity. Am J Physiol 1997; 272:E976-E980.
83. Matsukawa T, Sugiyama Y, Watanabe T, Kobayashi F, Mano T. Gender difference in age-related changes in muscle sympathetic nerve activity in healthy subjects. Am J Physiol 1998; 275:R1600-R1604.
84. Crampes F, Riviere D, Beauville M, Marceron M, Garrigues M. Lipolytic response of adipocytes to epinephrine in sedentary and exercise-trained subjects: sex-related differences. Eur J Appl Physiol Occup Physiol 1989; 59:249-255.
85. Lonnqvist F, Nyberg B, Wahrenberg H, Arner P. Catecholamine-induced lipolysis in adipose tissue of the elderly. J Clin Invest 1990; 85:1614-1621.
86. Jensen MD, Cryer PE, Johnson CM, Murray MJ. Effects of epinephrine on regional free fatty acid and energy metabolism in men and women. Am J Physiol 1996; 270:E259-E264.
87. Borsheim E, Lonnroth P, Knardahl S, Jansson PA. No difference in the lipolytic response to beta-adrenoceptor stimulation in situ but a delayed increase in adipose tissue blood flow in moderately obese compared with lean men in the postexercise period. Metabolism 2001; 49:579-87.
88. Goldstein DS. Plasma catecholamines and essential hypertension. An analytical review. Hypertension 1983; 5:86-99.
89. Esler M. The sympathetic system and hypertension. Am J Hypertens 2001; 13:99S-105S.
90. Franco-Morselli R, Elghozi JL, Joly E, Di Giuilio S, Meyer P. Increased plasma adrenaline concentrations in benign essential hypertension. Br Med J 1977; 2:1251-124.
91. Eliasson K, Hjemdahl P, Kahan T. Circulatory and sympathoadrenal responses to stress in borderline and established hypertension. J Hypertension 1983; 1:131-139.
92. Cerasola G, Cottone S, D’Ignoto G, Grasso L, Contorno A, Carone MB, Fulantelli MA. Role of epinephrine in the development of essential hypertension. J Clin Hy-pertens 1987; 3:670-680.
93. Nezu M, Miura Y, Adachi M, Adachi M, Kimura S, Toriyabe S, Ishizuka Y, Ohashi H, Sugawara T, Takahashi M. The effects of epinephrine on norepinephrine release in essential hypertension. Hypertension 1985; 7:187-195.
94. Jacobs MC, Lenders JW, Willemsen JJ, Thien T. Adrenomedullary secretion of epinephrine is increased in mild essential hypertension. Hypertension 1997; 29:1303-1308.
95. Goldstein DS, Levinson PD, Zimlichman R, Pitterman A, Stull R, Keiser HR. Clonidine suppression testing in essential hypertension. Ann Intern Med 1985; 102:42-49.
96. Goldstein DS, Grossman E, Listwak S, Folio CJ. Sympathetic reactivity during a yohimbine challenge test in essential hypertension. Hypertension 1991; 18 (suppl III):III-40-III-48.
97. Majewski H, Tung LH, Rand MJ. Hypertension through adrenaline activation of prejunctional beta-adrenoceptors. Clin Exp Pharmacol Physiol 1981; 8:463-468.
98. Majewski H, Rand MJ. A possible role of epinephrine in the development of hypertension. Med Res Rev 1986; 6:467-486.
99. Esler M, Eisenhofer G, Chin J, Jennings G, Meredith I, Cox H, Lambert G, Thompson J, Dart A. Is adrenaline released by sympathetic nerves in man? Clin Auton Res 1991; 1:103-108.
100. Eisenhofer G, Smolich JJ, Esler MD. Disposition of endogenous adrenaline compared to noradrenaline released by cardiac sympathetic nerves in the anaesthetized dog. Naunyn Schmiedebergs Arch Pharmacol 1992; 345:160-171.
101. Blankestijn PJ, Man in’t Veld AJ, Tulen J, van den Meiracker AH, Boomsma F, Moleman P, Ritsema van Eck HJ, Derkx FH, Mulder P, Lamberts SJ. Support for adrenaline-hypertension hypothesis: 18 hour pressor effect after 6 hours adrenaline infusion. Lancet 1988; 2:1386-1389.
102. van den Meiracker AH, Man in’t Veld AJ, Boomsma F, Blankestijn PJ, Schalekamp MA. Epinephrine-induced enhancement of sympathetic activity in humans: inhibition by nonselective as well as beta 1-selective beta-adrenoceptor blockade. J Car-diovasc Pharmacol 1990; 15:610-617.
103. Boudreau G, Peronnet F, De Champlain J, Nadeau R. Presynaptic effects of epinephrine on norepinephrine release from cardiac sympathetic nerves in dogs. Am J Physiol 1993; 265:H205-H211.
104. Floras JS. Epinephrine and the genesis of hypertension. Hypertension 1992; 19:1-18.
105. Goldstein DS, Golczynska A, Stuhlmuller J, Holmes C, Rea RF, Grossman E, Lenders J. A test of the “epinephrine hypothesis” in humans. Hypertension 1999; 33:36-43.
106. Stein MB, Asmundson GJ. Autonomic function in panic disorder: cardiorespiratory and plasma catecholamine responsivity to multiple challenges of the autonomic nervous system. Biol Psychiatry 1994; 36:548-558.
107. Roy-Byrne P, Cowley DS, Stein MB, Wingerson D, Veith R. Cardiovascular and catecholamine response to orthostasis in panic and obsessive-compulsive disorder and normal controls: effects of anxiety and novelty. Depress Anxiety 1997; 6:159-164.
108. Nesse RM, Cameron OG, Curtis GC, McCann DS, Huber-Smith MJ. Adrenergic function in patients with panic anxiety. Arch Gen Psychiatry 1984; 41:771-776.
109. Villacres EC, Hollifield M, Katon WJ, Wilkinson CW, Veith RC. Sympathetic nervous system activity in panic disorder. Psychiatry Res 1987; 21:313-321.
110. Nesse RM, Cameron OG, Buda AJ, McCann DS, Curtis GC, Huber-Smith MJ. Urinary catecholamines and mitral valve prolapse in panic-anxiety patients. Psychiatry Res 1985; 14:67-75.
111. Schneider P, Evans L, Ross-Lee L, Wiltshire B, Eadie M, Kenardy J, Hoey H. Plasma biogenic amine levels in agoraphobia with panic attacks. Pharmacopsychiatry 1987; 20:102-104.
112. Braune S, Albus M, Frohler M, Hohn T, Scheibe G. Psychophysiological and biochemical changes in patients with panic attacks in a defined situational arousal. Eur Arch Psychiatry Clin Neurosci 1994; 244:86-92.
113. Hoehn T, Braune S, Scheibe G, Albus M. Physiological, biochemical and subjective parameters in anxiety patients with panic disorder during stress exposure as compared with healthy controls. Eur Arch Psychiatry 1997; 247:264-274.
114. Wilkinson DJ, Thompson JM, Lambert GW, Jennings GL, Schwarz RG, Jefferys D, Turner AG, Esler MD. Sympathetic activity in patients with panic disorder at rest, under laboratory mental stress, and during panic attacks. Arch Gen Psychiatry 1998; 55:511-520.
115. Carlsson M, Carlsson A. Effects of mild stress on adrenal and heart catecholamines in male and female rats. J Neural Transm 1989; 77:217-226.
116. Dimsdale JE, Moss J. Plasma catecholamines in stress and exercise. JAMA 1980; 243:340-342.
117. Eisenhofer G, Lambie DG, Johnson RH. Beta-adrenoceptor responsiveness and plasma catecholamines as determinants of cardiovascular reactivity to mental stress. Clin Sci 1985; 69:483-492.
118. Maddock RJ, Carter CS, Magliozzi JR, Gietzen DW. Evidence that decreased function of lymphocyte beta adrenoreceptors reflects regulatory and adaptive processes in panic disorder with agoraphobia. Am J Psychiatry 1993; 150:1219-1225
119. Liebowitz MR, Gorman JM, Fyer AJ, Levitt M, Dillon D, Levy G, Appleby IL, Anderson S, Palij M, Davies SO. Lactate provocation of panic attacks. II. Biochemical and physiological findings. Arch Gen Psychiatry 1985; 42:709-719.
120. Coryell W, Coryell W, Noyes R, Clancy J. Panic disorder and mortality. Excess mortality in panic disorder. A comparison with primary unipolar depression. Arch Gen Psychiatry 1982; 39:701-703.
121. Fleet R, Lavoie K, Beitman BD. Is panic disorder associated with coronary artery disease? A critical review of the literature. J Psychosom Res 2001; 48:347-356.
122. Cryer PE, Gerich JE. Relevance of glucose counterregulatory systems to patients with diabetes: critical roles of glucagon and epinephrine. Diabetes Care 1983; 6:95-99.
123. Shamoon H, Friedman S, Canton C, Zacharowicz L, Hu M, Rossetti L. Increased epinephrine and skeletal muscle responses to hypoglycemia in non-insulin-dependent diabetes mellitus. J Clin Invest 1994; 93:2562-2571.
124. Bolli G, de Feo P, Compagnucci P, Cartechini MG, Angeletti G, Santeusanio F, Brunetti P, Gerich JE. Abnormal glucose counterregulation in insulin-dependent diabetes mellitus. Interaction of anti-insulin antibodies and impaired glucagon and epinephrine secretion. Diabetes 1983; 32:134-141.
125. Hirsch BR, Shamoon H. Defective epinephrine and growth hormone responses in type I diabetes are stimulus specific. Diabetes 1987; 36:20-26.
126. Kennedy FP, Bolli GB, Go VL, Cryer PE, Gerich JE. The significance of impaired pancreatic polypeptide and epinephrine responses to hypoglycemia in patients with insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1987; 64:602-608.
127. Kennedy FP, Go VL, Cryer PE, Bolli GB, Gerich JE. Subnormal pancreatic polypeptide and epinephrine responses to insulin-induced hypoglycemia identify patients with insulin-dependent diabetes mellitus predisposed to develop overt autonomic neuropathy. Ann Intern Med 1988; 108:54-58.
128. Hoeldtke RD, Boden G. Epinephrine secretion, hypoglycemia unawareness, and diabetic autonomic neuropathy. Ann Intern Med 1994; 120:512-517.
129. Hoeldtke RD, Boden G, Shuman CR, Owen OE. Reduced epinephrine secretion and hypoglycemia unawareness in diabetic autonomic neuropathy. Ann Intern Med 1982; 96:459-462.
130. Horie H, Hanafusa T, Matsuyama T, Namba M, Nonaka K, Tarui S, Yamatodani A, Wada H. Decreased response of epinephrine and norepinephrine to insulin-induced hypoglycemia in diabetic autonomic neuropathy. Horm Metab Res 1984; 16:398-401.
131. Ryder RE, Owens DR, Hayes TM, Ghatei MA, Bloom SR. Unawareness of hypo-glycaemia and inadequate hypoglycaemic counterregulation: no causal relation with diabetic autonomic neuropathy. Br Med J 1990; 301:783-787.
132. Scherbaum WA, Mogel H, Boehm BO, Hedderich U, Gluck M, Schernthaner G, Bottazzo GF, Pfeiffer EF. Autoantibodies to adrenal medullary and thyroid calcitonin cells in type I diabetes mellitus—a prospective study. J Autoimmun 1988; 1:219-230.
133. Brown FM, Vinik AI, Ganda OP, Adri MN, Rabinowe SL. Different effects of duration on prevalence of anti-adrenal medullary and pancreatic islet cell antibodies in type I diabetes mellitus. Horm Metab Res 1989; 21:434-437.
134. Brown FM, Smith AM, Longway S, Rabinowe SL. Adrenal medullitis in type I diabetes. J Clin Endocrinol Metab 1990; 71:1491-1495.
135. Ziegler MG, Lake CR, Kopin IJ. The sympathetic-nervous-system defect in primary orthostatic hypotension. N Engl J Med 1977; 296:293-297.
136. Polinsky RJ, Brown RT, Curras MT, Baser SM, Baucom CE, Hooper DR, Marini AM. Central and peripheral effects of arecoline in patients with autonomic failure. J Neurol Neurosurg Psychiatry 1991; 54:807-812.
137. Meredith IT, Esler MD, Cox HS, Lambert GW, Jennings GL, Eisenhofer G. Biochemical evidence of sympathetic denervation of the heart in pure autonomic failure. Clin Auton Res 1991; 1:187-194.
138. Polinsky RJ, Kopin IJ, Ebert MH, Weise V. The adrenal medullary response to hypoglycemia in patients with orthostatic hypotension. J Clin Endocrinol Metab 1980; 51:1401-1406.
139. Eisenhofer G, Lambie DG, Johnson RH, Tan E, Whiteside EA. Deficient catecholamine release as the basis of orthostatic hypotension in pernicious anaemia. J Neurol Neurosurg Psychiatry 1982; 45:1053-1055.
140. Sasaki K, Matsuhashi A, Murabayashi S, Aoyagi K, Baba T, Matsunaga M, Takebe K. Hormonal response to insulin-induced hypoglycemia in patients with Shy-Drager syndrome. Metabolism 1983; 32:977-981.
141. Guttman PH. Addison’s disease: A statistical analysis of five hundred and sixty-six cases and a study of the pathology. Arch Path 1930; 10:742-785.
142. Luft R, von Euler US. Urinary excretion of cateholamines during insulin hypoglycemia in five patients with Addison’s disease and in one patient after bilateral adrenalectomy. Acta Endocrinol 1957; 26:96-100.
143. Wegienka LC, Grasso SG, Forsham PH. Estimation of adrenomedullary reserve by infusion of 2-deoxy-D-glucose. J Clin Endocrinol Metab 1966; 26:37-45.
144. Bornstein SR, Breidert M, Ehrhart-Bornstein M, Kloos B, Scherbaum WA. Plasma catecholamines in patients with Addison’s disease. Clin Endocrinol 1995; 42:215-218.
145. Rudman D, Moffitt SD, Fernhoff PM, Blackston RD, Faraj BA. Epinephrine deficiency in hypocorticotropic hypopituitary children. J Clin Endocrinol Metab 1981; 53:722-728.
146. Szemeredi K, Bagdy G, Stull R, Calogero AE, Kopin IJ, Goldstein DS. Sympathoa-drenomedullary inhibition by chronic glucocorticoid treatment in conscious rats. Endocrinology 1988; 123:2585-2590.
147. Mathe AA, Knapp PH. Decreased plasma free fatty acids and urinary epinephrine in bronchial asthma. N Engl J Med 1969; 281:234-238.
148. Bornstein SR, Tajima T, Eisenhofer G, Haidan A, Aguilera G. Adrenomedullary function is severely impaired in 21-hydroxylase-deficient mice. FASEB J 1999; 13:1185-1194.
149. Merke DP, Chrousos GP, Eisenhofer G, Weise M, Keil MF, Rogol AD, Van Wyk JJ, Bornstein SR. Adrenomedullary dysplasia and hypofunction in patients with classic 21-hydroxylase deficiency. N Engl J Med 2001; 343:1362-1368.
150. Greenberg R, Rosenthal I, Falk GS. Electron microscopy of human tumors secreting catecholamines: correlation with biochemical data. J Neuropathol Exp Neurol 1969; 28:475-500.
151. Lauper NT, Tyce GM, Sheps SG, Carney JA. Pheochromocytoma. Fine structural, biochemical and clinical observations. Am J Cardiol 1972; 30:197-204.
152. Kvale WF, Roth GM, Manger WM, Priestley JT. Pheochromocytoma. Circulation 1956; 14:622-630.
153. Gifford RW, Kvale WF, Maher FT, Roth GM, Priestley JT. Clinical features, diagnosis, and treatment of pheochromocytoma. A review of 76 cases. Mayo Clin Proc 1964; 39:281-302.
154. Manger WM, Gifford RW. Clinical and Experimental Pheochromocytoma. Cambridge, MA: Blackwell Science, 1996.
155. Choyke PL, Glenn GM, Walther MM, Patronas NJ, Linehan WM, Zbar B. von Hippel-Lindau disease: genetic, clinical, and imaging features. Radiology 1995; 194:629-642.
156. Neumann HP, Berger DP, Sigmund G, Blum U, Schmidt D, Parmer RJ, Volk B, Kirste G. Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease. N Engl J Med 1993; 329:1531-1538.
157. Walther MM, Reiter R, Keiser HR, Choyke PL, Venzon D, Hurley K, Gnarra JR, Reynolds JC, Glenn GM, Zbar B, Linehan WM. Clinical and genetic characterization of pheochromocytoma in von Hippel-Lindau families: comparison with sporadic pheochromocytoma gives insight into natural history of pheochromocytoma. J Urol 1999; 162:659-664.
158. Pomares FJ, Canas R, Rodriguez JM, Hernandez AM, Parrilla P, Tebar FJ. Differences between sporadic and multiple endocrine neoplasia type 2A phaeochromocy-toma. Clin Endocrinol 1998; 48:195-200.
159. Calmettes C, Ponder BA, Fischer JA, Raue F. Early diagnosis of the multiple endocrine neoplasia type 2 syndrome: consensus statement. European Community Concerted Action: Medullary Thyroid Carcinoma. Eur J Clin Invest 1992; 22:755-760.
160. Huson SM, Compston DA, Harper PS. A genetic study of von Recklinghausen neurofibromatosis in south east Wales. II. Guidelines for genetic counselling. J Med Genet 1989; 26:712-721.
161. Walther MM, Herring J, Enquist E, Keiser HR, Linehan WM. von Recklinghausen’s disease and pheochromocytomas. J Urol 1999; 162:1582-1586.
162. Kimura N, Miura Y, Nagatsu I, Nagura H. Catecholamine synthesizing enzymes in 70 cases of functioning and non-functioning phaeochromocytoma and extra-adrenal paraganglioma. Virchows Arch A Pathol Anat Histopathol 1992; 421:25-32.
163. Ito Y, Fujimoto Y, Obara T. The role of epinephrine, norepinephrine, and dopamine in blood pressure disturbances in patients with pheochromocytoma. World J Surg 1992; 16:759-763.
164. Proye C, Fossati P, Fontaine P, Lefebvre J, Decoulx M, Wemeau JL, Dewailly D, Rwamasirabo E, Cecat P. Dopamine-secreting pheochromocytoma: an unrecognized entity? Classification of pheochromocytomas according to their type of secretion. Surgery 1986; 100:1154-1162.
165. Yasunari K, Kohno M, Minami M, Kano H, Ohhira M, Nakamura K, Yoshikawa J. A dopamine-secreting pheochromocytoma. J Cardiovasc Pharmacol 2001; 36(suppl 2):S75-S77.
166. Feldman JM. Phenylethanolamine-N-methyltransferase activity determines the epinephrine concentration of pheochromocytomas. Res Commun Chem Pathol Pharmacol 1981; 34:389-398.
167. Eisenhofer G, Walther MM, Huynh TT, Li ST, Bornstein SR, Vortmeyer A, Man-nelli M, Goldstein DS, Linehan WM, Lenders JW, Pacak K. Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes. J Clin Endocrinol Metab 2001; 86:1999-2008.
168. Page LB, Raker JW, Berberich FR. Pheochromocytoma with predominant epinephrine secretion. Am J Med 1969; 47:648-652.
169. Aronoff SL, Passamani E, Borowsky BA, Weiss AN, Roberts R, Cryer PE. Norepinephrine and epinephrine secretion from a clinically epinephrine- secreting pheochromocytoma. Am J Med 1980; 69:321-324.
170. Anton AH, Greer M, Sayre DF, Williams CM. Dihydroxyphenylalanine secretion in a malignant pheochromocytoma. Am J Med 1967; 42:469-475.
171. Goldstein DS, Stull R, Eisenhofer G, Sisson JC, Weder A, Averbuch SD, Keiser HR. Plasma 3,4-dihydroxyphenylalanine (dopa) and catecholamines in neuroblastoma or pheochromocytoma. Ann Intern Med 1986; 105:887-888.
172. McClean DR, Sinclair LM, Yandle TG, Nicholls MG. Malignant phaeochromocy-toma with high circulating DOPA, and clonidine-suppressible noradrenaline. Blood Press 1995; 4:215-217.
173. John H, Ziegler WH, Hauri D, Jaeger P. Pheochromocytomas: can malignant potential be predicted? Urology 1999; 53:679-683.
174. Lenders JW, Keiser HR, Goldstein DS, Willemsen JJ, Friberg P, Jacobs MC, Kloppenborg PW, Thien T, Eisenhofer G. Plasma metanephrines in the diagnosis of pheochromocytoma. Ann Intern Med 1995; 123:101-109.
175. Eisenhofer G, Lenders JW, Linehan WM, Walther MM, Goldstein DS, Keiser HR. Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. N Engl J Med 1999; 340:1872-1879.
176. Raber W, Raffesberg W, Bischof M, Scheuba C, Niederle B, Gasic S, Waldhausl W, Roden M. Diagnostic efficacy of unconjugated plasma metanephrines for the detection of pheochromocytoma. Arch Intern Med 2000; 160:2957-2963.
177. Pacak K, Linehan WM, Eisenhofer G, Walther MM, Goldstein DS. Recent Advances in Genetics, Diagnosis, Localization, and Treatment of Pheochromocytoma. Ann Intern Med 2001; 134:315-329.
178. Eisenhofer G. Biochemical diagnosis of pheochromocytoma. In: Pacak K, moderator. Recent advances in genetics, diagnosis, localization, and treatment of pheochro-mocytoma. Ann Intern Med 2001; 134:317-320.
179. Bravo EL, Tarazi RC, Fouad FM, Vidt DG, Gifford RW Jr. Clonidine-suppression test: a useful aid in the diagnosis of pheochromocytoma. N Engl J Med 1981; 305:623-626.
180. Grossman E, Goldstein DS, Hoffman A, Keiser HR. Glucagon and clonidine testing in the diagnosis of pheochromocytoma. Hypertension 1991; 17:733-741.
181. Manger WM, Gifford RWJr. Pheochromocytoma: current diagnosis and management. Clev Clin J Med 1993; 60:365-378.
182. Fink IJ, Reinig JW, Dwyer AJ, Doppman JL, Linehan WM, Keiser HR. MR imaging of pheochromocytomas. J Comput Assist Tomogr 1985; 9:454-458.
183. Schmedtje JF, Jr., Sax S, Pool JL, Goldfarb RA, Nelson EB. Localization of ectopic pheochromocytomas by magnetic resonance imaging. Am J Med 1987; 83:770-772.
184. Sisson JC, Frager MS, Valk TW, Gross MD, Swanson DP, Wieland DM, Tobes MC, Beierwaltes WH, Thompson NW. Scintigraphic localization of pheochromocytoma. N Engl J Med 1981; 305:12-17.
185. Shulkin BL, Shapiro B. Current concepts on the diagnostic use of MIBG in children. J Nucl Med 1998; 39:679-688.
186. Shapiro B, Copp JE, Sisson JC, Eyre PL, Wallis J, Beierwaltes WH. Iodine-131 metaiodobenzylguanidine for the locating of suspected pheochromocytoma: experience in 400 cases. J Nucl Med 1985; 26:576-585.
187. Eisenhofer G, Pacak K, Goldstein DS, Chen C, Shulkin B. 1231-MIBG scintigraphy of catecholamine systems: impediments to applications in clinical medicine. Eur J Nucl Med 2000; 27:611-612.
188. Shulkin BL, Wieland DM, Schwaiger M, Thompson NW, Francis IR, Haka MS, Rosenspire KC, Shapiro B, Sisson JC, Kuhl DE. PET scanning with hydrox-yephedrine: an approach to the localization of pheochromocytoma. J Nucl Med 1992; 33:1125-1131.
189. Adams S, Baum R, Rink T, Schumm-Drager PM, Usadel KH, Hor G. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med 1998; 25:79-83.
190. Goldstein DS, Cannon RO, Quyyumi A, Chang P, Duncan M, Brush JE, Jr., Eisenhofer G. Regional extraction of circulating norepinephrine, DOPA, and dihydrox-yphenylglycol in humans. J Auton Nerv Syst 1991; 34:17-35.
191. Eisenhofer G, Aneman A, Friberg P, Hooper D, F~andriks L, Lonroth H, Hunyady B, Mezey E. Substantial production of dopamine in the human gastrointestinal tract. J Clin Endocrinol Metab 1998; 42:374-377.